Proteomics International Laboratories (PIQ) Q2 2025 TU earnings summary

Executive summary

• Achieved breakthrough results for endometriosis and diabetic kidney disease diagnostics, with peer-reviewed publications validating high accuracy of PromarkerEndo and PromarkerD tests.

• OxiDx test demonstrated world-first capability to detect muscle damage in elite athletes, with results published and further studies underway.

• Strengthened leadership with new Chair, independent director, Chief Commercial Officer, and Clinical Pathologist appointments.

• Cash reserves bolstered by $2.16 million R&D tax incentive, supporting commercialisation milestones.

Financial highlights

• Cash receipts from customers for the quarter were $285,000, up from $253,000 in the previous quarter.

• Net operating cash inflow of $246,000, reversing a $1.46 million outflow in the prior quarter.

• R&D expenditure for the quarter was $1.14 million, with total R&D spend YTD at $2.15 million.

• Cash reserves at 31 December 2024 stood at $5.33 million, up from $5.10 million at 30 September.

Outlook and guidance

• PromarkerD launch in Australia and USA targeted for Q1 CY25, with US reference lab and CLIA accreditation in progress.

• PromarkerEndo launch in Australia targeted for Q2 CY25, with clinical validation and licensing discussions ongoing.

• PromarkerEso launch in Australia targeted for Q1 CY25, with ISO 15189 accreditation underway.

• OxiDx test launch in Australia planned for mid-2025, with proof-of-concept studies in progress.